secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001193125-25-263684
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics Q3 2025 net income $15.9M; vopimetostat mPFS 7.2 mo in pancreatic; cash runway into 2028
--------------------------------------------------------------------------------

- Net income $15.9M ($0.14 basic EPS) vs net loss $29.2M in Q3 2024; nine-month net loss $62.8M.
- Collaboration revenue $53.8M (Q3 2024: $11.6M) as Gilead collaboration truncated; all deferred revenue recognized.
- Vopimetostat in 2L MTAP-del pancreatic cancer showed median PFS 7.2 months; 49% ORR and mPFS 9.1 mo in histology-selective cohort.
- October 2025 financing raised $225M gross ($212M net); cash, equivalents and marketables $152.8M as of Sept 30, extending runway into 2028.
- TNG456 granted Orphan Drug Designation for malignant glioma; pivotal pancreatic study for vopimetostat anticipated to start 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000119312525263684/0001193125-25-263684-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000119312525263684/tngx-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-263684

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer